Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Диабетическая нефропатия: вопросы обратимости
Диабетическая нефропатия: вопросы обратимости
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Excerpts from the United States Renal Data System 2007 annual data report. Am J Kidney Dis 2008; 51 (Suppl. 1): S1–320.
2. Бибков Б.Т., Томилина Н.А. Состояние заместительной терапии больных с хронической почечной недостаточностью в Российской Федерации в 1998–2007 гг. Нефрология и Диализ, 2009; 3: 146–221.
3. Дедов И.И., Сунцов Ю.И., Маслова О.В. Скрининг осложнений сахарного диабета как метод оценки лечебно-профилактической помощи больным. Проблемы эндокринологии, 2010; 1: 3–8.
4. Tervaert TW, Mooyaart AL, Amann K et al. On behalf of the Renal Pathology Society. Pathologic Classification of Diabetic Nephropathy. J Am Soc Nephrol 2010; 21 (4): 556–63.
5. Giorgino F, Laviola L, Cavallo Perin P et al. Factors associated with progression to macroalbuminuria in microalbuminuric type 1 diabetic patients: the EURODIAB Prospective Complications Study. Diabetologia 2004; 47: 1020–8.
6. Gæde P, Tarnow L, Vedel P, Parving HH, Pedersen O: Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant 2004; 19: 2784–8.
7. Araki S, Haneda M, Sugimoto T et al. Factors Associated With Frequent Remission of Microalbuminuria in Patients With Type 2 Diabetes. Diabetes 2005; 54: 2983–7.
8. Yamada T, Komatsu M, Komiya I et al. Development, Progression, and Regression of Microalbuminuria in Japanese Patients With Type 2 Diabetes Under Tight Glycemic and Blood Pressure Control. The Kashiwa Study Diabetes Care 2005; 11 (28): 2733–8.
9. de Zeeuw D, Remuzzi G, Parving HH et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65: 2309–20.
10. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560–72.
11. Zoungas S, Chalmers J, Pate A, Marre M, Mogensen CE et al. On behalf of the ADVANCE Collaborative Group. Intensive glucose control is renoprotective in type 2 diabetes: new analyses from ADVANCE. EASD 2010; Abstract.
12. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998; 339 (2): 69–75.
13. Shikata K, Haneda M, Koya D et al. Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan): Rationale and study design. Diabetes Research and Clinical Practice 2010; 87: 228–32.
14. http://www.georgeinstitute.org.au/our-work/our-divisions/ cardiovascular/our-projects/advance
2. Бибков Б.Т., Томилина Н.А. Состояние заместительной терапии больных с хронической почечной недостаточностью в Российской Федерации в 1998–2007 гг. Нефрология и Диализ, 2009; 3: 146–221.
3. Дедов И.И., Сунцов Ю.И., Маслова О.В. Скрининг осложнений сахарного диабета как метод оценки лечебно-профилактической помощи больным. Проблемы эндокринологии, 2010; 1: 3–8.
4. Tervaert TW, Mooyaart AL, Amann K et al. On behalf of the Renal Pathology Society. Pathologic Classification of Diabetic Nephropathy. J Am Soc Nephrol 2010; 21 (4): 556–63.
5. Giorgino F, Laviola L, Cavallo Perin P et al. Factors associated with progression to macroalbuminuria in microalbuminuric type 1 diabetic patients: the EURODIAB Prospective Complications Study. Diabetologia 2004; 47: 1020–8.
6. Gæde P, Tarnow L, Vedel P, Parving HH, Pedersen O: Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant 2004; 19: 2784–8.
7. Araki S, Haneda M, Sugimoto T et al. Factors Associated With Frequent Remission of Microalbuminuria in Patients With Type 2 Diabetes. Diabetes 2005; 54: 2983–7.
8. Yamada T, Komatsu M, Komiya I et al. Development, Progression, and Regression of Microalbuminuria in Japanese Patients With Type 2 Diabetes Under Tight Glycemic and Blood Pressure Control. The Kashiwa Study Diabetes Care 2005; 11 (28): 2733–8.
9. de Zeeuw D, Remuzzi G, Parving HH et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65: 2309–20.
10. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560–72.
11. Zoungas S, Chalmers J, Pate A, Marre M, Mogensen CE et al. On behalf of the ADVANCE Collaborative Group. Intensive glucose control is renoprotective in type 2 diabetes: new analyses from ADVANCE. EASD 2010; Abstract.
12. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998; 339 (2): 69–75.
13. Shikata K, Haneda M, Koya D et al. Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan): Rationale and study design. Diabetes Research and Clinical Practice 2010; 87: 228–32.
14. http://www.georgeinstitute.org.au/our-work/our-divisions/ cardiovascular/our-projects/advance
Авторы
М.В.Шестакова
ФГБУ Эндокринологический научный центр Минздравсоцразвития РФ
ФГБУ Эндокринологический научный центр Минздравсоцразвития РФ
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.